Form 4: NewAmsterdam Pharma Officer Trades Shares

Louise Kooij, Chief Accounting Officer at NewAmsterdam Pharma, executed a series of transactions involving the purchase and sale of ordinary shares, including those acquired through stock options, under a Rule 10b5-1 trading plan.

Summary

• Louise Frederika Kooij, Chief Accounting Officer at NewAmsterdam Pharma Co. N.V., reported transactions on May 26, 2026.
• She acquired 60,000 ordinary shares at a price of $10 per share and an additional 5,000 ordinary shares at $10.90 per share.
• Concurrently, she disposed of 65,000 ordinary shares at a weighted average price of $35.69 per share, with individual transactions ranging from $35.12 to $36.09.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on February 23, 2026.
• Following these transactions, Kooij beneficially owns 24,353 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by an officer can be a negative signal, the execution under a pre-established Rule 10b5-1 plan mitigates concerns about insider trading and suggests a planned financial management strategy rather than a reaction to company performance.

Positives

• The officer acquired additional shares, indicating a potential belief in the company's future value.
• The sale of shares was conducted under a pre-arranged Rule 10b5-1 plan, suggesting a structured and non-insider trading approach to managing personal holdings.

Negatives

• A significant number of shares were sold at a price considerably higher than the purchase price of newly acquired shares, potentially indicating profit-taking.
• The disposal of 65,000 shares represents a substantial reduction in the officer's direct holdings.

Risks

• The filing does not explicitly mention any new risks or challenges.
• The sale of a large number of shares by a key officer could be perceived negatively by the market, although it was executed under a 10b5-1 plan.

Future Outlook

The filing itself is a report of past transactions and does not contain forward-looking statements or guidance regarding the company's future financial performance. The Rule 10b5-1 plan indicates a structured approach to future potential transactions.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
• Reported transactions executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a Chief Accounting Officer is a common practice to diversify holdings or manage personal finances without creating the appearance of trading on material non-public information. The specific details of the transactions, including the volume and pricing, are crucial for market participants to assess insider sentiment.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by a key officer as a sign of reduced confidence, although the Rule 10b5-1 plan provides context that may lessen this concern.
• Employees: Similar to shareholders, may view insider sales with caution.
• Management: The Chief Accounting Officer is managing personal financial affairs in a structured manner.

Next Steps

• The reporting person may continue to execute transactions under the Rule 10b5-1 plan.
• The company may be required to provide further information upon request from the SEC or security holders regarding the specific details of the share sales.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Rule 10b5-1, NewAmsterdam Pharma, Louise Kooij, Ordinary Shares, Beneficial Ownership, Securities Transaction